Allosteric modulators for
human health
About us
Addex Corporate Presentation
Overview
Our people
Executive Officers
Non-Executive Directors
Contact
Privacy Policy
Careers
Pipeline
Clinical and Pre-Clinical Pipeline
Research And Development
Technology
Allosteric modulation
Publications
Partners & collaboration
Investors
Addex Corporate Presentation
Stock Data
Press releases
Ad hoc announcements (Art. 53 L.R)
Events
Financial Reports
Analyst Reports
General Meetings
SEC / SIX Filings
Guide to US ADSS for Six Shareholders
Register for email news
Corporate Governance
Contact
Media
Press releases
Contact
Press releases
All Years
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
2006
2005
2004
2003
2002
Please select year
02.23
2018
Addex Publishes Extraordinary General Meeting Invitation
02.15
2018
Addex Launches CHF40 million Capital Increase with Commitments from Specialist US Healthcare Investors
02.07
2018
Addex Appoints Jean-Philippe Rocher as Co-Head of Discovery and Member of the Executive Management
02.05
2018
Addex Provides Key Financial Indicators and Trading Update
02.02
2018
Van Leeuwenhoeck Issues Equity Research Note Highlighting Value of Recent Indivior Strategic Partnership on GABAB PAM
01.08
2018
Addex Therapeutics Equity Research Report Update Issued by valuationLAB
01.03
2018
Addex and Indivior Sign Strategic Partnership to Accelerate Development of GABAB PAMs as Addiction Treatments
10.18
2017
Van Leeuwenhoeck Issues Initiation of Coverage Research Report on Addex Therapeutics and Estimated ADXN Share Price of CHF 11.5 per Share
10.03
2017
Addex Therapeutics ADX71441 Program Awarded $5.3 Million Grant from US National Institute on Drug Abuse to Support Human Studies for the Treatment of Cocaine Use Disorder
09.26
2017
Addex Therapeutics Reports First Half 2017 Operating Highlights and Financial Results
Previous
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
Next
Back